The Alzheimer's treatments of the future
The FDA is expected to grant full approval to Leqembi, an Alzheimer’s drug from Eisai and Biogen.
Source: politico.com
Page 2 - Memory Disorders Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Memory Disorders Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Memory Disorders Program Today - Breaking & Trending Today
CMS open to Medicare negotiation transparency
The top Medicare official tasked with heading CMS’ drug price negotiation group signaled the agency might loosen its proposed requirement to restrict drug companies from disclosing details about the negotiation process.
Source: politico.com
Milken study will advance research on link between diabetes, Alzheimer's
A Milken professor will continue a 30-year study researching the relationship between Alzheimer's disease with prediabetes and Type 2 diabetes.
Source: gwhatchet.com
Understanding the Link Between Personal Finances and Early Alzheimer's
Can changes in the way a person manages their personal finances lead to an early diagnosis of Alzheimer’s disease? Georgetown researchers are developing machine learning algorithms to find out.
Source: georgetown.edu
Will cost keep new Alzheimer's drug from patients?
Leqembi’s manufacturers estimate the drug will be available by Jan. 23 and have priced the biweekly infusion at $26,500 annually.
Source: politico.com